Gå frakoblet med Player FM -appen!
From the helm: Immutep's (ASX:IMM) Executive Director & CEO Marc Voigt
Manage episode 324711669 series 2611018
In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.
Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.
In this video Marc discusses:
- (0:40) What IMM does and its key strength in the market
- (1:27) The impact of the FDA's recent feedback on its lead product
- (2:53) IMM's collaborations with big pharma names like Pfizer & Merck
- (4:03) When to expect data from its current clinical trials
- (5:10) What's coming up for IMM
Note: This interview was filmed on 22 March 2022.
57 episoder
Manage episode 324711669 series 2611018
In this instalment of our From the helm series, Bell Direct’s Sophia Mavridis speaks to Immutep's (ASX:IMM) Executive Director and CEO, Marc Voigt.
Global biotechnology company, Immutep is a leading developer of autoimmune and cancer immunotherapy treatments. The business has been gaining a lot of attention lately as its lead product is in its late-stage clinical trials for metastatic breast cancer.
In this video Marc discusses:
- (0:40) What IMM does and its key strength in the market
- (1:27) The impact of the FDA's recent feedback on its lead product
- (2:53) IMM's collaborations with big pharma names like Pfizer & Merck
- (4:03) When to expect data from its current clinical trials
- (5:10) What's coming up for IMM
Note: This interview was filmed on 22 March 2022.
57 episoder
Alle episoder
×Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.